Post-Marketing Surveillance (Usage Results Study) of Brigatinib in the Treatment of Adult Patients for Approved Indications in South Korea
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Brigatinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Takeda
- 15 Jan 2025 Planned number of patients changed from 616 to 257.
- 29 Sep 2021 Planned number of patients changed from 600 to 616.
- 29 Sep 2021 Planned End Date changed from 1 Aug 2024 to 26 Aug 2026.